Randomised clinical trial: exploratory phase 2 study of ONO‐2952 in diarrhoea‐predominant irritable bowel syndrome

BACKGROUND: ONO‐2952 is a novel and selective inhibitor of translocator protein 18 kDa that reduces stress‐induced defecation and visceral hyperalgesia in rat models. AIM: To evaluate the efficacy and safety of ONO‐2952 in females with irritable bowel syndrome with diarrhoea in an exploratory proof‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Whitehead, W. E., Duffy, K., Sharpe, J., Nabata, T., Bruce, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Randomised Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5157770/
https://www.ncbi.nlm.nih.gov/pubmed/27910150
http://dx.doi.org/10.1111/apt.13839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5157770/
https://www.ncbi.nlm.nih.gov/pubmed/27910150
http://dx.doi.org/10.1111/apt.13839

Ejemplares similares